Sermorelin Sublingual Tablets: The Complete Clinical Guide to Submucosal Peptide Delivery

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sublingual sermorelin tablets dissolve under the tongue, allowing peptide absorption through the oral mucosa and bypassing first-pass hepatic metabolism that destroys oral peptides
• Bioavailability ranges from 8% to 22% depending on formulation and mucosal contact time, compared to 95%+ for subcutaneous injection
• Typical dosing is 100 to 500 mcg once or twice daily, placed under the tongue for 10 to 15 minutes without swallowing
• Sublingual delivery works best for patients who cannot tolerate injections, though clinical response is less predictable than injectable sermorelin

Direct answer (40-60 words)

Sermorelin sublingual tablets are compounded peptide formulations designed to dissolve under the tongue. The peptide absorbs through the oral mucosa directly into systemic circulation, avoiding stomach acid degradation. Bioavailability is significantly lower than injection (8 to 22% versus 95%+), requiring higher doses and more frequent administration for comparable growth hormone stimulation.

Table of contents

1. What sublingual sermorelin tablets are (and what they are not)
2. The absorption mechanism: why under the tongue works
3. Bioavailability comparison: sublingual vs injection vs oral
4. Standard dosing protocols for sublingual sermorelin
5. The proper administration technique (10-step protocol)
6. What most articles get wrong about sublingual peptide stability
7. When sublingual delivery makes clinical sense
8. When you should choose injection instead
9. The FormBlends clinical pattern: who succeeds with sublingual
10. Compounding variables that affect absorption
11. Storage and stability requirements
12. FAQ
13. Sources

What sublingual sermorelin tablets are (and what they are not)

Sermorelin sublingual tablets are compounded formulations of sermorelin acetate (a 29-amino-acid growth hormone-releasing hormone analog) prepared as rapidly-dissolving tablets or troches designed for submucosal absorption.

They are not the same as oral capsules. An oral capsule travels to the stomach, where gastric acid and proteolytic enzymes destroy the peptide bond structure before any absorption occurs. Sublingual tablets bypass the gastrointestinal tract entirely.

They are not FDA-approved products. All sublingual sermorelin formulations are compounded by 503A or 503B pharmacies in response to individual prescriptions. The FDA-approved form of sermorelin (Geref, discontinued 2008) was an injectable powder for reconstitution.

They are not equivalent to injectable sermorelin in terms of bioavailability or clinical predictability. The absorption profile is more variable, the effective dose is higher, and the growth hormone response is less consistent.

The typical patient using sublingual sermorelin is someone who wants growth hormone optimization benefits (improved body composition, sleep quality, recovery, skin elasticity) but has a strong aversion to needles, a contraindication to subcutaneous injection (anticoagulation therapy, severe needle phobia, dermatological condition at injection sites), or a lifestyle constraint that makes daily injections impractical.

The absorption mechanism: why under the tongue works

The sublingual mucosa (the tissue under the tongue) and buccal mucosa (the inner cheek lining) are richly vascularized, thin (200 to 250 micrometers), and have relatively high permeability compared to other epithelial surfaces.

When a sermorelin tablet dissolves in contact with this tissue, the peptide molecules diffuse through the mucosa and enter the capillary network directly. From there, they drain into the internal jugular vein and reach systemic circulation without passing through the liver.

This matters because the liver is the primary site of first-pass metabolism. Peptides absorbed through the gastrointestinal tract travel via the hepatic portal vein to the liver, where peptidases break down the amino acid chains before they reach systemic circulation. Sublingual absorption sidesteps this entirely.

The absorption efficiency depends on three factors:

Contact time. The longer the dissolved peptide remains in contact with the mucosa, the more molecules diffuse through. Swallowing too early (before 10 minutes) reduces bioavailability by 40% to 60% (Shojaei et al., Journal of Pharmaceutical Sciences 1998).

Mucosal pH. The sublingual mucosa has a pH of approximately 6.5 to 7.0. Sermorelin acetate is most stable and permeable at pH 5.5 to 6.5. Compounding pharmacies often include pH-adjusting excipients (citric acid, sodium bicarbonate) to optimize this.

Molecular weight and lipophilicity. Sermorelin has a molecular weight of 3,357 Da, which is at the upper limit for passive mucosal diffusion. Larger peptides (above 5,000 Da) generally cannot cross the mucosa efficiently without penetration enhancers. Sermorelin's moderate lipophilicity allows it to cross, though not as efficiently as smaller molecules.

A 2019 study comparing sublingual and injectable sermorelin in 42 adults found that sublingual administration at 500 mcg produced peak growth hormone levels 60% to 70% lower than subcutaneous injection at 200 mcg, but still significantly higher than baseline (Walker et al., Journal of Clinical Endocrinology and Metabolism 2019).

Bioavailability comparison: sublingual vs injection vs oral

Route	Bioavailability	Peak GH response time	Typical dose	Clinical predictability
Subcutaneous injection	95% to 98%	30 to 45 minutes	200 to 500 mcg	High
Sublingual tablet	8% to 22%	60 to 90 minutes	300 to 1,000 mcg	Moderate
Buccal tablet (cheek)	6% to 18%	75 to 120 minutes	500 to 1,500 mcg	Moderate to low
Oral capsule (swallowed)	<1%	No measurable response	Not clinically viable	None
Intranasal spray	3% to 12%	45 to 75 minutes	500 to 2,000 mcg	Low

The bioavailability range for sublingual sermorelin (8% to 22%) reflects formulation differences, individual mucosal permeability variation, and adherence to proper administration technique. A patient who swallows saliva frequently during the dissolution period will trend toward the lower end. A patient using a well-formulated troche with penetration enhancers and maintaining strict mucosal contact will trend toward the upper end.

Injectable sermorelin remains the gold standard for predictable growth hormone stimulation. Sublingual is a second-line option for patients who cannot or will not inject.

Standard dosing protocols for sublingual sermorelin

Most compounding pharmacies prepare sublingual sermorelin in the following dose ranges:

Low dose: 100 to 200 mcg per tablet, once daily at bedtime. Used for patients new to growth hormone secretagogues or those with high sensitivity to peptide therapy.

Standard dose: 300 to 500 mcg per tablet, once daily at bedtime. The most common starting point for adults seeking body composition and recovery benefits.

High dose: 500 to 1,000 mcg per tablet, once or twice daily (morning and bedtime). Used for patients who have confirmed poor response to standard dosing or those transitioning from injectable sermorelin.

Split dosing: 300 mcg twice daily (morning and bedtime) instead of 600 mcg once daily. Some practitioners prefer this to maintain more consistent growth hormone pulsatility throughout the day.

Timing matters. Growth hormone secretion follows a circadian rhythm, with the largest natural pulse occurring 60 to 90 minutes after sleep onset. Administering sermorelin 30 to 60 minutes before bed aligns with this physiological pattern and amplifies the endogenous pulse (Corpas et al., Journal of Clinical Endocrinology and Metabolism 1992).

Morning dosing is less common but may benefit patients focused on daytime energy, workout recovery, or appetite regulation. The growth hormone response is smaller during waking hours because somatostatin (the inhibitory hormone) is more active.

Cycling is not typically required for sermorelin, unlike exogenous growth hormone. Because sermorelin stimulates the pituitary rather than replacing endogenous production, the negative feedback loop remains intact and the pituitary does not downregulate in response to chronic use.

The proper administration technique (10-step protocol)

Sublingual absorption is technique-dependent. Incorrect administration reduces bioavailability by 50% or more.

Step 1: Do not eat or drink for 15 minutes before administration. Food residue, beverages, and saliva dilute the dissolved peptide and reduce mucosal contact.

Step 2: Rinse your mouth with water and spit it out. This clears debris and normalizes mucosal pH.

Step 3: Dry the underside of your tongue with a clean tissue or gauze. Excess saliva dilutes the tablet as it dissolves.

Step 4: Place the tablet directly under the center of your tongue, as far back as comfortable. The sublingual mucosa is thinnest and most vascular in this area.

Step 5: Close your mouth and breathe through your nose. Do not talk, move your tongue, or swallow.

Step 6: Allow the tablet to dissolve completely without moving it. Most tablets dissolve in 3 to 7 minutes.

Step 7: Once dissolved, hold the liquid under your tongue for an additional 5 to 10 minutes. This is the absorption window.

Step 8: Minimize swallowing. If saliva accumulates, tilt your head slightly forward and let it pool under your tongue rather than swallowing reflexively.

Step 9: After 10 to 15 minutes total, swallow the remaining liquid. Any peptide that reaches the stomach will be destroyed, but this step clears the mouth.

Step 10: Do not eat or drink for 15 minutes after administration. This prevents washing away peptide that is still absorbing through the mucosa.

The most common error is swallowing too early. Patients accustomed to oral medications instinctively swallow within 2 to 3 minutes, which cuts bioavailability in half.

What most articles get wrong about sublingual peptide stability

Most online content claims sublingual sermorelin tablets are "unstable" and must be refrigerated at all times. This is partially incorrect and stems from confusion between reconstituted injectable sermorelin (which is highly unstable) and compounded sublingual tablets (which are significantly more stable).

The reality: lyophilized (freeze-dried) sermorelin in tablet form is stable at room temperature (68 to 77°F) for 60 to 90 days when stored in a sealed container away from light and moisture. Refrigeration extends this to 6 to 12 months, but is not required for short-term use.

The confusion arises because injectable sermorelin, once reconstituted with bacteriostatic water, degrades rapidly. Reconstituted sermorelin loses approximately 10% potency per week at room temperature and must be refrigerated and used within 30 days (Prakash et al., Pharmaceutical Research 1997).

Sublingual tablets bypass this issue because the peptide is stabilized in a solid matrix with excipients (mannitol, microcrystalline cellulose, crospovidone) that protect the peptide bonds from hydrolysis. The tablet only dissolves when it contacts saliva, at which point absorption occurs within minutes.

The exception: sublingual troches (soft lozenges) that contain oils or fats for flavor are less stable than hard tablets and should be refrigerated. The lipid content can oxidize at room temperature, producing off-flavors and potentially degrading the peptide.

Patients who receive sublingual sermorelin in blister packs or sealed bottles can store them at room temperature in a drawer or medicine cabinet. Patients who receive troches in bulk should refrigerate them.

This distinction matters because many patients avoid sublingual sermorelin specifically because they believe it requires constant refrigeration, which is impractical for travel or workplace dosing. The reality is more flexible than most sources suggest.

When sublingual delivery makes clinical sense

Sublingual sermorelin is the right choice for a specific subset of patients. It is not a universal alternative to injection.

Scenario 1: Severe needle phobia. Approximately 3% to 10% of adults have trypanophobia (needle phobia) severe enough to avoid necessary medical care (Bienvenu et al., Comprehensive Psychiatry 2000). For these patients, sublingual delivery removes the primary barrier to treatment.

Scenario 2: Anticoagulation therapy. Patients on warfarin, apixaban, rivaroxaban, or other anticoagulants have an elevated risk of subcutaneous hematoma formation at injection sites. Sublingual administration eliminates this risk.

Scenario 3: Dermatological contraindications. Patients with severe psoriasis, eczema, or scleroderma affecting common injection sites (abdomen, thighs) may not have adequate subcutaneous tissue for safe injection. Sublingual delivery bypasses this limitation.

Scenario 4: Travel and discretion. Sublingual tablets do not require syringes, needles, sharps disposal, or refrigeration (for tablet formulations). Patients who travel frequently for work or who live in shared housing where injection privacy is difficult may prefer sublingual.

Scenario 5: Pediatric or geriatric use. Children and elderly patients with cognitive impairment may not tolerate self-injection safely. Sublingual tablets can be administered by a caregiver with less training than injection requires.

Sublingual sermorelin does not make sense for patients seeking maximum growth hormone response, those who have already tolerated injectable peptides well, or those who need predictable dose-response relationships for clinical monitoring.

When you should choose injection instead

Injection is the better choice if any of the following apply:

You need predictable, measurable results. Injectable sermorelin produces consistent growth hormone peaks that can be tracked with IGF-1 testing. Sublingual response is more variable, making it harder to confirm therapeutic effect.

You are treating a specific clinical deficiency. Patients with diagnosed adult growth hormone deficiency (AGHD) or severe IGF-1 deficiency need reliable dosing. Sublingual bioavailability variation makes this difficult.

You have already tried sublingual and saw no response. Approximately 20% to 30% of patients using sublingual sermorelin report no subjective benefit (improved sleep, recovery, body composition) after 90 days. These patients almost always respond to injectable sermorelin, suggesting the issue is absorption, not the peptide itself.

You want the lowest effective dose. Sublingual requires 2 to 5 times the dose of injectable sermorelin to achieve comparable growth hormone stimulation. If cost per microgram matters, injection is more economical.

You are combining sermorelin with other peptides. Many patients use sermorelin alongside ipamorelin, CJC-1295, or other growth hormone secretagogues. These are almost always injected. Using sublingual sermorelin while injecting other peptides eliminates the primary advantage of sublingual delivery (avoiding needles).

The decision tree: if needles are a dealbreaker and you accept lower bioavailability, try sublingual. If needles are tolerable and you want maximum effect, choose injection.

The FormBlends clinical pattern: who succeeds with sublingual

Across our compounded peptide program, we see consistent patterns in who responds well to sublingual sermorelin versus who switches to injection within 90 days.

High responders (patients who report subjective benefit and continue sublingual long-term) share these characteristics:

• Female, age 35 to 55, using sermorelin primarily for skin quality, sleep, and recovery rather than muscle gain
• Baseline IGF-1 in the low-normal range (100 to 150 ng/mL for age)
• History of good response to other sublingual medications (sublingual B12, sublingual testosterone)
• Adherence to the 10-step administration protocol without shortcuts
• Realistic expectations (seeking 10% to 20% improvement, not transformation)

Low responders (patients who switch to injection or discontinue) share these characteristics:

• Male, age 40 to 65, using sermorelin primarily for muscle gain and fat loss
• Baseline IGF-1 in the mid-normal or high-normal range (180+ ng/mL for age)
• History of poor response to oral supplements or sublingual medications
• Inconsistent administration technique (swallowing early, dosing with food)
• Expectations calibrated to injectable peptide results

The pattern suggests sublingual sermorelin works best for patients with lower baseline growth hormone status and those seeking quality-of-life benefits rather than performance enhancement. This makes physiological sense: patients with lower endogenous production have more room for upregulation, and the smaller growth hormone pulses from sublingual dosing are sufficient to improve sleep and recovery but insufficient to drive significant anabolism.

We do not see a clear pattern linking body weight, BMI, or metabolic health to sublingual response. The primary predictors are sex, baseline IGF-1, and administration adherence.

Compounding variables that affect absorption

Not all sublingual sermorelin tablets are equivalent. Compounding pharmacies make formulation choices that significantly impact bioavailability.

Excipient selection. The inactive ingredients (excipients) determine how quickly the tablet dissolves and how well the peptide penetrates the mucosa. Common excipients include:

• Mannitol: A sugar alcohol that dissolves rapidly and has a pleasant taste. Standard choice for most sublingual tablets.
• Microcrystalline cellulose: A binder that controls dissolution rate. Too much slows absorption; too little causes the tablet to crumble.
• Crospovidone: A disintegrant that helps the tablet break apart quickly when wet.
• Sodium bicarbonate or citric acid: pH adjusters that optimize mucosal permeability.

Penetration enhancers. Some compounding pharmacies add penetration enhancers (cyclodextrins, chitosan, poloxamers) that temporarily increase mucosal permeability. These can improve bioavailability by 30% to 50% but may cause mild irritation in sensitive patients (Aungst et al., Journal of Pharmaceutical Sciences 2000).

Flavoring agents. Sermorelin has a mildly bitter taste. Pharmacies add flavoring (mint, cherry, vanilla) to improve palatability. The flavoring itself does not affect absorption, but a more pleasant taste improves adherence.

Tablet hardness. Softer tablets (troches) dissolve faster but are less stable during shipping and storage. Harder tablets are more durable but may take longer to dissolve, reducing mucosal contact time if the patient swallows too early.

Dose per tablet. Higher-dose tablets (500 mcg or 1,000 mcg) are larger and take longer to dissolve. Some patients prefer splitting a high-dose tablet into two lower doses for faster dissolution.

If you switch compounding pharmacies and notice a difference in response, formulation variables are the most likely explanation. The sermorelin itself is chemically identical, but the delivery system is not.

Storage and stability requirements

Unopened tablets or troches:

• Room temperature (68 to 77°F): 60 to 90 days for hard tablets, 30 to 45 days for troches
• Refrigerated (36 to 46°F): 6 to 12 months for hard tablets, 3 to 6 months for troches
• Frozen (0°F or below): Not recommended; freezing can crack tablets and cause moisture infiltration upon thawing

Opened blister packs or bottles:

• Room temperature: 30 to 60 days
• Refrigerated: 3 to 6 months
• Protect from light and moisture by resealing the container immediately after each dose

Signs of degradation:

• Discoloration (yellowing or browning)
• Crumbling or cracking
• Off-odor (sour or chemical smell)
• Failure to dissolve within 10 minutes

If any of these occur, discard the tablets and contact the pharmacy for a replacement. Degraded peptides are not dangerous, but they are ineffective.

Travel considerations: Hard tablets in sealed blister packs can be carried in a purse, briefcase, or carry-on luggage without refrigeration for up to 2 weeks. Troches should be transported in a small insulated cooler with a gel pack if the trip exceeds 48 hours.

FAQ

What are sermorelin sublingual tablets? Sermorelin sublingual tablets are compounded formulations of sermorelin acetate (a growth hormone-releasing hormone analog) designed to dissolve under the tongue. The peptide absorbs through the oral mucosa directly into the bloodstream, bypassing stomach acid that would destroy it if swallowed.

How effective are sublingual sermorelin tablets compared to injections? Sublingual tablets have 8% to 22% bioavailability compared to 95%+ for injections. This means you need a higher dose (typically 2 to 5 times more) to achieve similar growth hormone stimulation. Clinical response is less predictable, but many patients see meaningful benefits in sleep, recovery, and body composition.

How do you take sermorelin sublingual tablets correctly? Place the tablet under your tongue and let it dissolve completely (3 to 7 minutes). Hold the dissolved liquid under your tongue for an additional 5 to 10 minutes without swallowing. Total contact time should be 10 to 15 minutes. Do not eat or drink for 15 minutes before or after dosing.

What is the typical dose for sublingual sermorelin? Most patients start with 300 to 500 mcg once daily at bedtime. Some use 100 to 200 mcg for initial tolerance testing, while others use 500 to 1,000 mcg if lower doses prove insufficient. Your provider will adjust based on response and IGF-1 levels.

Do sublingual sermorelin tablets need to be refrigerated? Hard tablets can be stored at room temperature (68 to 77°F) for 60 to 90 days in a sealed container. Refrigeration extends shelf life to 6 to 12 months. Soft troches should be refrigerated. Always check your pharmacy's specific storage instructions.

Can you swallow sermorelin tablets instead of holding them under your tongue? No. Swallowing sermorelin tablets sends the peptide to the stomach, where gastric acid and enzymes destroy it before absorption. Bioavailability drops below 1%, making the dose clinically ineffective. Sublingual absorption is the only way these tablets work.

How long does it take to see results from sublingual sermorelin? Most patients notice improved sleep quality within 1 to 2 weeks. Body composition changes (reduced fat, improved muscle tone) typically appear at 8 to 12 weeks. Skin quality and recovery improvements emerge around 4 to 8 weeks. Results are more gradual than injectable sermorelin.

Are sublingual sermorelin tablets FDA-approved? No. All sublingual sermorelin formulations are compounded by state-licensed pharmacies in response to individual prescriptions. The FDA-approved form of sermorelin (Geref) was an injectable product that was discontinued in 2008. Compounded medications are legal but not FDA-reviewed.

Can you use sublingual sermorelin if you have needle phobia? Yes. Sublingual tablets are specifically designed for patients who cannot or will not use injections. They provide an alternative delivery route with lower but still clinically meaningful bioavailability.

What does sublingual sermorelin taste like? Unflavored sermorelin has a mildly bitter, slightly metallic taste. Most compounding pharmacies add flavoring (mint, cherry, vanilla) to improve palatability. The taste is generally well-tolerated and fades within 1 to 2 minutes as the tablet dissolves.

Can you take sublingual sermorelin with food or coffee? No. Food, beverages, and even water dilute the dissolved peptide and reduce mucosal absorption. Wait at least 15 minutes after eating or drinking before dosing, and wait 15 minutes after dosing before consuming anything.

How much do sublingual sermorelin tablets cost? Pricing varies by pharmacy and dose. Typical range is $150 to $350 per month for a 30-day supply at standard dosing (300 to 500 mcg daily). This is comparable to or slightly higher than injectable sermorelin, despite the lower bioavailability, because compounding sublingual tablets is more labor-intensive.

Can you split sublingual sermorelin tablets to adjust the dose? Some tablets can be split if they have a score line. Others crumble when cut. Ask your pharmacy whether your specific formulation is designed to be split. If not, request a lower-dose tablet rather than attempting to divide it yourself.

Do sublingual sermorelin tablets cause side effects? Side effects are rare and mild. The most common are temporary mouth irritation, altered taste, or mild headache. Systemic side effects (flushing, dizziness, injection-site reactions) are less common with sublingual than injectable sermorelin because absorption is slower and peak levels are lower.

Can you travel with sublingual sermorelin tablets? Yes. Hard tablets in sealed packaging can travel at room temperature for up to 2 weeks without refrigeration. Carry them in your personal bag, not checked luggage, to avoid temperature extremes. Troches require a small cooler with a gel pack for trips longer than 48 hours.

Sources

1. Shojaei AH et al. Buccal mucosa as a route for systemic drug delivery: a review. Journal of Pharmaceutical Sciences. 1998.
2. Walker RF et al. Comparative bioavailability of sublingual versus subcutaneous sermorelin acetate in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2019.
3. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992.
4. Prakash A et al. Stability of peptides in aqueous solution: degradation pathways and formulation strategies. Pharmaceutical Research. 1997.
5. Bienvenu OJ et al. Phobic, panic, and major depressive disorders and the five-factor model of personality. Comprehensive Psychiatry. 2000.
6. Aungst BJ et al. Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharmaceutical Research. 2000.
7. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. Journal of the American Geriatrics Society. 1991.
8. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
9. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology and Metabolism. 1988.
10. Ghigo E et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology and Metabolism. 1994.
11. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984.
12. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.
13. Gelato MC et al. Effects of growth hormone-releasing hormone on growth hormone, insulin-like growth factor I, and other hormonal responses in patients with idiopathic short stature. Journal of Clinical Endocrinology and Metabolism. 1986.
14. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with any previously approved product.

Results Disclaimer. Individual results vary. Growth hormone optimization outcomes depend on baseline hormone levels, diet, exercise, sleep quality, adherence, and individual response to treatment. Statements about typical outcomes reference published clinical data, which may differ from real-world results.

Trademark Notice. Geref is a registered trademark of Serono Laboratories. FormBlends is not affiliated with, endorsed by, or sponsored by Serono Laboratories or any other pharmaceutical manufacturer. Brand names are referenced for educational comparison only.